Detalles de la búsqueda
1.
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
Oncologist
; 28(5): e242-e253, 2023 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36961477
2.
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study.
Oncology
; 100(2): 124-130, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34844255
3.
Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study.
Value Health
; 25(6): 1002-1009, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35667773
4.
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Breast Cancer Res Treat
; 180(3): 597-609, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32100144
5.
Accounting for Uncertainty in Decision Analytic Models Using Rank Preserving Structural Failure Time Modeling: Application to Parametric Survival Models.
Value Health
; 21(1): 105-109, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29304934
6.
Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients.
Health Qual Life Outcomes
; 16(1): 179, 2018 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30208899
7.
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.
J Manag Care Spec Pharm
; : 1-10, 2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38807035
8.
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis.
JCO Precis Oncol
; 7: e2200651, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37384865
9.
Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
JCO Precis Oncol
; 7: e2200436, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689698
10.
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
Pharmacoeconomics
; 40(Suppl 1): 69-89, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34658008
11.
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
Pharmacoeconomics
; 40(Suppl 1): 11-38, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761360
12.
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers.
Pharmacoeconomics
; 40(Suppl 1): 39-67, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34907515
13.
Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling.
Med Decis Making
; 42(2): 194-207, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34666553
14.
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom.
Pharmacoeconomics
; 40(Suppl 1): 91-102, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34658007
15.
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.
Cancers (Basel)
; 14(7)2022 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35406565
16.
Mixture Cure Models in Oncology: A Tutorial and Practical Guidance.
Pharmacoecon Open
; 5(2): 143-155, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33638063
17.
Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
J Med Econ
; 23(5): 464-473, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31951770
18.
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
J Med Econ
; 22(7): 625-637, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30836031
19.
Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
Pharmacoeconomics
; 40(Suppl 1): 119, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35217993
20.
Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.
Adv Ther
; 34(3): 753-764, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28205056